Takeda Pharmaceutical Co ADR Dossier - Source-backed chat

Takeda Pharmaceutical Co ADR

TAKTokyo Stock Exchange

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.40

Intrinsic Value $6.89median of 6 methods · middle span $0-$20based on filings through 31 Mar 2025

Market Price $17.86Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 61% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-61%)

Data confidence Sign in to view data confidence

Market Cap $57B

Shares Outstanding 3.2B diluted

Next Earnings Date29 Oct 2026

Last ex-dividend31 Mar 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Takeda has crossed an important pipeline inflection point: ORZEYFUL and MIMRYLO received U.S. FDA approval in August 2026, while zasocitinib remains positioned for a 2026 filing and possible first-half 2027 launch. However, the transition is not yet proven commercially. First-quarter core revenue declined 0.5% at constant exchange rates, FY2026 guidance still anticipates a low-single-digit core-revenue decline and a 5%-8% core-operating-profit decline at constant exchange rates, and the AMITIZA litigation remains unresolved. A Hold stance balances substantially improved pipeline de-risking against launch execution, mature-product erosion and legal uncertainty.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.90

Mean target$21.90

High · most bullish analyst$22.97

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.9020%

DEA scheduling or commercial execution delays ORZEYFUL availability, MIMRYLO adoption is slower than expected, and mature-product erosion drives constant-currency revenue below management's low-single-digit decline framework. An adverse AMITIZA judgment or a larger provision adds pressure, while any zasocitinib filing delay weakens confidence in the next growth wave.

Base CaseCentral scenario

$21.9055%

Matches the consensus mean

ORZEYFUL and MIMRYLO launch broadly on schedule, but payer access, physician adoption and launch investment produce a gradual rather than immediate contribution. Core in-line products largely offset VYVANSE erosion, keeping FY2026 performance near management guidance, while zasocitinib progresses toward a potential first-half 2027 launch.

Bull CaseUpside scenario

$22.9725%

ORZEYFUL becomes commercially available promptly after DEA scheduling and demonstrates strong adoption as the first approved therapy addressing the underlying orexin deficiency in narcolepsy type 1. MIMRYLO converts its differentiated efficacy into meaningful uptake in polycythemia vera, while zasocitinib advances on schedule. These launches begin offsetting mature-product erosion earlier than management guidance implies.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

ORZEYFUL received U.S. FDA approval in August 2026 as the first and only medicine indicated to address the underlying cause of narcolepsy type 1; Takeda expected DEA scheduling within 90 days.
MIMRYLO received U.S. FDA approval in August 2026, supported by a Phase 3 clinical-response rate of 76.9% during weeks 20-32.
Takeda's launch portfolio extends beyond the two approvals: management continued to target a 2026 zasocitinib filing and anticipated a commercial launch in the first half of 2027.

Key Investment Risks

Underlying momentum remains pressured: FY2026 first-quarter core revenue declined 0.5% at constant exchange rates, with VYVANSE loss of exclusivity identified as the principal headwind.
The investment case now depends on successful commercialization of newly approved products, including launch timing, payer access, physician adoption and post-launch safety execution.
The unresolved AMITIZA antitrust matter caused Takeda to record an additional JPY 402.5 billion legal provision for FY2025 and remains subject to post-trial proceedings and appeal.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.